Nanoscope Therapeutics licenses optogenetic technology
September 30, 2024
September 30, 2024
MUNICH, Germany, Sept. 30 [Category: Science] (TNSres) -- The Max Planck Society issued the following news:
The US biotech company Nanoscope Therapeutics Inc. has acquired a license for the CatCh technology from Max Planck Innovation, the technology transfer organization of the Max Planck Society. Based on research findings from the Max Planck Institute for Biophysics, and the pioneering work of Prof. Ernst Bamberg in the field of optogenetics, this patented technology enhances the . . .
The US biotech company Nanoscope Therapeutics Inc. has acquired a license for the CatCh technology from Max Planck Innovation, the technology transfer organization of the Max Planck Society. Based on research findings from the Max Planck Institute for Biophysics, and the pioneering work of Prof. Ernst Bamberg in the field of optogenetics, this patented technology enhances the . . .